R&D pipeline

The UCB pipeline delivers:

•  a promising portfolio targeting severe diseases and addressing unmet medical needs
•  focus on neurological and immunological diseases
•  more convenient and effective treatments for patients and specialists.

UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.